Review
Medicine, General & Internal
Michal Jarocki, Julia Karska, Szymon Kowalski, Pawel Kielb, Lukasz Nowak, Wojciech Krajewski, Jolanta Saczko, Julita Kulbacka, Tomasz Szydelko, Bartosz Malkiewicz
Summary: Molecular and immunological research are crucial for understanding the pathophysiology of tumor cells. The relationship between renal cell carcinoma (RCC) and the immune mediator IL-17 is complex, as IL-17 can have both promoting and inhibitory effects on RCC development.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Merve Hasanov, Denai R. Milton, William H. Sharfman, Bret Taback, Lee D. Cranmer, Gregory A. Daniels, Lawrence Flaherty, Sigrun Hallmeyer, Mohammed Milhem, Lynn Feun, Ralph Hauke, Gary Doolittle, Nancy Gregory, Sapna Patel
Summary: The study showed that sequential administration of High Dose Aldesleukin and ipilimumab in metastatic melanoma patients may enhance long-term disease control. One-year overall survival, progression-free survival, and objective response rate were all higher in the study, with similar frequencies of adverse events observed between the two treatment arms.
Review
Oncology
Adam M. Kase, Daniel J. George, Sundhar Ramalingam
Summary: Biological discoveries in the past two decades have revolutionized the treatment of renal cell carcinoma. The development of agents targeting pro-angiogenic pathways and immunogenicity have significantly impacted the management of clear cell renal cell carcinoma. Clear cell is the most common subtype, and therapies have focused on the Von Hippel Lindau gene alterations, leading to the approval of tyrosine kinase inhibitors and immune checkpoint inhibitors. Combinations of these treatments have become the standard of care for advanced clear cell renal cell carcinoma, with promising new therapeutic targets under development.
Article
Oncology
Ann W. Silk, Brendan Curti, Jennifer Bryan, Tracie Saunders, Weichung Shih, Michael P. Kane, Phoebe Hannon, Christopher Fountain, Jessica Felcher, Andrew Zloza, Howard L. Kaufman, Janice M. Mehnert, David F. McDermott
Summary: This study aimed to evaluate the safety profile of high-dose interleukin-2 (HD IL-2) in combination with pembrolizumab for the treatment of unresectable or metastatic melanoma. The results showed that this combination therapy was feasible and well-tolerated in patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Okki Cho, Joong-Woon Lee, Han -Sol Kim, Young-Jin Jeong, Tae-Hwe Heo
Summary: In this study, the researchers investigated the inhibitory effects of chelerythrine (CHE) on IL-2 activity and its potential as an anticancer agent. They found that CHE selectively inhibited the interaction between IL-2 and IL-2R alpha and directly bound to IL-2. CHE inhibited the proliferation and signaling of CTLL-2 cells, suppressed IL-2 activity in different immune cells, and prevented the conversion of CD4+ T cells into regulatory T cells. In mouse models, CHE reduced tumor growth, upregulated the expression of IFN-gamma and cytotoxic molecules, and synergistically increased antitumor activity when combined with a PD-1 inhibitor.
Review
Oncology
Kevin K. Zarrabi, Oladimeji Lanade, Daniel M. Geynisman
Summary: Kidney cancer is a common type of cancer, with clear cell renal cell carcinoma being the most frequent form. Treatment options for newly diagnosed metastatic clear cell renal cell carcinoma include surgery, radiation, and systemic therapies. The complexity of treatment selection has increased due to the diverse biology of tumors. The therapeutic landscape for metastatic renal cell carcinoma has rapidly evolved, with combination therapy strategies involving immune checkpoint blockade and anti-angiogenesis targeted therapy becoming the standard of care.
Editorial Material
Cell Biology
Melita Irving, Yaquelin Ortiz-Miranda, George Coukos
Summary: IL-2 is a potent growth factor for T cells. Recent research has revealed that immune checkpoint blockade treatment relies on the presence of IL-2, and engineered mesenchymal stem cells can effectively deliver IL-2 directly in advanced tumors, rescuing CD8(+) T cell responsiveness to anti-PD-L1 antibody treatment.
NATURE CELL BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
In-Ho Kim, Hyo Jin Lee
Summary: Approximately 400,000 patients are diagnosed with kidney cancer annually worldwide, resulting in approximately 170,000 deaths. Clear cell RCC is the most common subtype, accounting for about 85% of metastatic RCC cases. Immunotherapy with checkpoint inhibitors has shown promising results and become the standard of care for advanced clear cell RCC.
Review
Urology & Nephrology
Xiaoyang Wang, Robert Lopez, Rebecca A. Luchtel, Sassan Hafizi, Benjamin Gartrell, Niraj Shenoy
Summary: This article reviews the advancements in targeted therapies and immune checkpoint inhibitors in the treatment landscape of Renal Cell Carcinoma (RCC) over the last decade, emphasizing the importance of understanding the mechanisms adopted by RCC cells to evade immune killing and exploring current clinical trials and future directions in the field.
KIDNEY INTERNATIONAL
(2021)
Article
Immunology
Hugo S. Duarte, Cassia R. P. Veiga, Claudimar P. Veiga, Alberto J. A. Wainstein, Ana P. Drummond-Lage
Summary: This study evaluated the toxicity profile associated with PD-1 inhibitors in patients treated at an oncology service in Belo Horizonte. Fatigue was identified as the most prevalent adverse event, with different toxicities appearing at different times during treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Editorial Material
Oncology
Viktor Gruenwald, Walter J. Storkus
Summary: This collection focuses on the immunobiology of renal cell carcinoma (RCC), the impact of immunotherapy in treating RCC, and the identification of biomarkers related to patient outcomes and response to immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Alexander Chehrazi-Raffle, Luis Meza, Marice Alcantara, Nazli Dizman, Paulo Bergerot, Nicholas Salgia, JoAnn Hsu, Nora Ruel, Sabrina Salgia, Jasnoor Malhotra, Ewa Karczewska, Marcin Kortylewski, Sumanta Pal
Summary: This study found that specific plasma cytokines were associated with clinical benefit in patients with renal cell carcinoma receiving VEGF-TKI or ICI therapy. These findings support further investigation into plasma cytokines as potential biomarkers for renal cell carcinoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Biochemistry & Molecular Biology
R. Dummer, D. E. Gyorki, J. Hyngstrom, A. C. Berger, R. Conry, L. Demidov, A. Sharma, S. A. Treichel, H. Radcliffe, K. S. Gorski, A. Anderson, E. Chan, M. Faries, M. I. Ross
Summary: The study found that intralesional injection of an oncolytic virus prior to surgery is clinically beneficial for patients with locally advanced, resectable melanoma, leading to improved recurrence-free survival.
Article
Medicine, Research & Experimental
Liu-xun Chen, Shen-jie Zeng, Xv-dong Liu, Hai-bin Tang, Jia-wu Wang, Qing Jiang
Summary: This study characterizes the intercellular communications within the ccRCC microenvironment and shows their impact on prognosis and immunotherapy efficacy. It reveals a potential relationship between the VHL phenotype and the landscape of cell-cell communication. Moreover, these communication molecules also influence the development and infiltration of T cells and myeloid cells. Different clusters of intercellular communications have significant predictive value for prognosis and distinguish immunotherapy efficiency.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Bin Zheng, Fang Xie, Fajuan Cheng, Jianwei Wang, Zhongshun Yao, Wei He, Zhihong Niu
Summary: This study comprehensively assessed the tumor microenvironment of kidney cancer, identified two immune-related hub genes - IGLL5 and IL2RA, and validated their clinical application value in ccRCC and pRCC. Drug response was also predicted based on selected genes, revealing novel drug candidates for RCC treatment.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
